JP6795585B2 - Ａｘｌインヒビタおよび免疫チェックポイントモジュレータまたは腫瘍溶解性ウィルスによる併用療法 - Google Patents

Ａｘｌインヒビタおよび免疫チェックポイントモジュレータまたは腫瘍溶解性ウィルスによる併用療法 Download PDF

Info

Publication number
JP6795585B2
JP6795585B2 JP2018513923A JP2018513923A JP6795585B2 JP 6795585 B2 JP6795585 B2 JP 6795585B2 JP 2018513923 A JP2018513923 A JP 2018513923A JP 2018513923 A JP2018513923 A JP 2018513923A JP 6795585 B2 JP6795585 B2 JP 6795585B2
Authority
JP
Japan
Prior art keywords
substituted
benzo
cases
dihydro
triazole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018513923A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018521116A (ja
Inventor
ブラッドレー ロレンス，ジェイムス
ブラッドレー ロレンス，ジェイムス
ガウスダル，グロ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BerGenBio ASA
Original Assignee
BerGenBio ASA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BerGenBio ASA filed Critical BerGenBio ASA
Publication of JP2018521116A publication Critical patent/JP2018521116A/ja
Application granted granted Critical
Publication of JP6795585B2 publication Critical patent/JP6795585B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2018513923A 2015-05-29 2016-05-27 Ａｘｌインヒビタおよび免疫チェックポイントモジュレータまたは腫瘍溶解性ウィルスによる併用療法 Active JP6795585B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB1509338.8 2015-05-29
GBGB1509338.8A GB201509338D0 (en) 2015-05-29 2015-05-29 Combination therapy
GB1516442.9 2015-09-16
GBGB1516442.9A GB201516442D0 (en) 2015-05-29 2015-09-16 Combination therapy
PCT/GB2016/051542 WO2016193680A1 (en) 2015-05-29 2016-05-27 Combination therapy with axl inhibitor and immune checkpoint modulator or oncolytic virus

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020038089A Division JP7229194B2 (ja) 2015-05-29 2020-03-05 Ａｘｌインヒビタおよび免疫チェックポイントモジュレータまたは腫瘍溶解性ウィルスによる併用療法

Publications (2)

Publication Number Publication Date
JP2018521116A JP2018521116A (ja) 2018-08-02
JP6795585B2 true JP6795585B2 (ja) 2020-12-02

Family

ID=53677482

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018513923A Active JP6795585B2 (ja) 2015-05-29 2016-05-27 Ａｘｌインヒビタおよび免疫チェックポイントモジュレータまたは腫瘍溶解性ウィルスによる併用療法
JP2020038089A Active JP7229194B2 (ja) 2015-05-29 2020-03-05 Ａｘｌインヒビタおよび免疫チェックポイントモジュレータまたは腫瘍溶解性ウィルスによる併用療法
JP2022114274A Active JP7549627B2 (ja) 2015-05-29 2022-07-15 Ａｘｌインヒビタおよび免疫チェックポイントモジュレータまたは腫瘍溶解性ウィルスによる併用療法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020038089A Active JP7229194B2 (ja) 2015-05-29 2020-03-05 Ａｘｌインヒビタおよび免疫チェックポイントモジュレータまたは腫瘍溶解性ウィルスによる併用療法
JP2022114274A Active JP7549627B2 (ja) 2015-05-29 2022-07-15 Ａｘｌインヒビタおよび免疫チェックポイントモジュレータまたは腫瘍溶解性ウィルスによる併用療法

Country Status (5)

Country Link
US (4) US20180153888A1 (enExample)
EP (2) EP3302481A1 (enExample)
JP (3) JP6795585B2 (enExample)
GB (2) GB201509338D0 (enExample)
WO (1) WO2016193680A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020105211A (ja) * 2015-05-29 2020-07-09 ベルゲンビオ エイエスエイＢｅｒＧｅｎＢｉｏ ＡＳＡ Ａｘｌインヒビタおよび免疫チェックポイントモジュレータまたは腫瘍溶解性ウィルスによる併用療法

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6885390B2 (ja) * 2016-02-26 2021-06-16 小野薬品工業株式会社 Ａｘｌ阻害剤と免疫チェックポイント阻害剤とを組み合わせて投与することを特徴とする癌治療のための医薬
US10639368B2 (en) 2016-05-27 2020-05-05 Agenus Inc. Anti-TIM-3 antibodies and methods of use thereof
IL265800B2 (en) 2016-10-11 2023-10-01 Agenus Inc Anti-LAG-3 antibodies and methods of using them
US11576873B2 (en) 2017-03-31 2023-02-14 The Curators Of The University Of Missouri Compositions for the treatment of drug-resistant tumors and methods of use thereof
WO2019039525A1 (ja) * 2017-08-23 2019-02-28 小野薬品工業株式会社 Ａｘｌ阻害剤を有効成分として含むがん治療剤
WO2019074116A1 (ja) 2017-10-13 2019-04-18 小野薬品工業株式会社 Ａｘｌ阻害剤を有効成分として含む固形がん治療剤
BR112020026641A2 (pt) * 2018-06-27 2021-03-30 Oscotec Inc. Derivados de piridopirimidinona para o uso como inibidores de axl
UY38349A (es) 2018-08-30 2020-03-31 Array Biopharma Inc Compuestos de pirazolo[3,4-b]piridina como inhibidores de cinasas tam y met
GB201912059D0 (en) 2019-08-22 2019-10-09 Bergenbio As Combaination therapy of a patient subgroup
GB202004189D0 (en) 2020-03-23 2020-05-06 Bergenbio As Combination therapy
GB202006072D0 (en) * 2020-04-24 2020-06-10 Bergenbio Asa Method of selecting patients for treatment with cmbination therapy
GB202104037D0 (en) 2021-03-23 2021-05-05 Bergenbio Asa Combination therapy
EP4359439A1 (en) 2021-06-24 2024-05-01 Yeda Research and Development Co. Ltd Combination therapy for the treatment of cancer comprising an anti-egfr antibody and an axl-inhibitor
GB202209285D0 (en) 2022-06-24 2022-08-10 Bergenbio Asa Dosage regimen for AXL inhibitor
AR129722A1 (es) 2022-06-28 2024-09-18 Arcus Biosciences Inc Compuestos inhibidores de axl
KR20240156104A (ko) * 2023-04-21 2024-10-29 아주대학교산학협력단 면역 관문 억제제 저항성 극복을 위한 암의 예방 또는 치료용 약학적 조성물

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2226211A1 (de) 1972-05-30 1973-12-13 Basf Ag N-substituierte iminocumarinfarbstoffe
AU2905199A (en) * 1999-03-15 2000-10-04 Trustees Of The University Of Pennsylvania, The Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject
US6149495A (en) 1999-03-15 2000-11-21 Austin; Joseph James Confetti and theatrical snow delivery device
EP1382969A1 (en) 2002-07-17 2004-01-21 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Diagnosis and prevention of cancer cell invasion
AU2003286746A1 (en) 2002-10-29 2004-05-25 Rigel Pharmaceuticals, Inc. Modulators of angiogenesis and tumorigenesis
WO2007030680A2 (en) 2005-09-07 2007-03-15 Rigel Pharmaceuticals, Inc. Triazole derivatives useful as axl inhibitors
CA2647282A1 (en) * 2006-04-05 2007-10-11 Pfizer Products Inc. Ctla4 antibody combination therapy
AU2007307652A1 (en) 2006-10-10 2008-04-17 Squicor Compositions and methods for treating and diagnosing cancers
US8097630B2 (en) 2006-10-10 2012-01-17 Rigel Pharmaceuticals, Inc. Pinane-substituted pyrimidinediamine derivatives useful as Axl inhibitors
JP2008130120A (ja) 2006-11-17 2008-06-05 Sharp Corp 光ピックアップ装置
WO2008080134A2 (en) 2006-12-22 2008-07-03 Rigel Pharmaceuticals, Inc. 4-amin0-2- (hetero) arylamino-5- (hetero) arylthiazoles useful as axl inhibitors
US9650391B2 (en) 2006-12-29 2017-05-16 Rigel Pharmaceuticals Inc. N3-heteroaryl substituted triazoles and N5-heteroaryl substituted triazoles useful as Axl inhibitors
CA2710230C (en) 2006-12-29 2016-02-23 Rigel Pharmaceuticals, Inc. Bridged bicyclic aryl and bridged bicyclic heteroaryl substituted triazoles useful as axl inhibitors
PL2078010T3 (pl) * 2006-12-29 2014-07-31 Rigel Pharmaceuticals Inc Triazole podstawione policyklicznym heteroarylem użyteczne jako inhibitory Axl
ES2558477T3 (es) 2006-12-29 2016-02-04 Rigel Pharmaceuticals, Inc. Triazoles sustituidos útiles como inhibidores de AXL
ES2406930T3 (es) 2006-12-29 2013-06-10 Rigel Pharmaceuticals, Inc. Triazoles sustituidos con arilo bicíclico y heteroarilo bicíclico útiles como inhibidores de AXL
EP2102356A2 (en) 2007-01-09 2009-09-23 Brystol-Myers Squibb Company Identification of polynucleotides for predicting activity of compounds that interact with and/or modulate protein tyrosine kinases and/or protein tyrosine kinase pathways in prostate cells
JP2010523712A (ja) * 2007-04-13 2010-07-15 スーパージェン， インコーポレイテッド 癌または過剰増殖の治療に有用なａｘｌキナーゼ阻害剤
EP2137535B1 (en) 2007-04-13 2015-06-03 Dana-Farber Cancer Institute, Inc. Receptor tyrosine kinase profiling
SI2205592T1 (sl) 2007-10-26 2013-09-30 Rigel Pharmaceuticals, Inc. Triazoli substituirani s policikličnim arilom in triazoli substituirani s policikličnim heteroarilom uporabni kot Axl inhibitorji
NZ599628A (en) 2007-11-12 2013-11-29 U3 Pharma Gmbh Axl antibodies
PE20091024A1 (es) 2007-11-15 2009-08-12 Chugai Pharmaceutical Co Ltd Anticuerpos monoclonales que se unen a anexelekto y sus usos
SI2851374T1 (sl) 2007-12-14 2017-08-31 Bristol-Myers Squibb Company Vezavne molekule k humanemu ox40 receptorju
US8735064B2 (en) 2007-12-24 2014-05-27 Bergenbio As Methods for creating and identifying functional RNA interference elements
US8546433B2 (en) * 2009-01-16 2013-10-01 Rigel Pharmaceuticals, Inc. Axl inhibitors for use in combination therapy for preventing, treating or managing metastatic cancer
KR20120035145A (ko) 2009-05-11 2012-04-13 우드라이 파마 게엠베하 인간화 ａｘｌ 항체
JP5669732B2 (ja) 2009-05-15 2015-02-12 中外製薬株式会社 抗ａｘｌ抗体
AU2010303149B2 (en) * 2009-09-30 2016-08-04 Board Of Regents, The University Of Texas System Combination immunotherapy for the treatment of cancer
US20130064831A1 (en) 2010-05-17 2013-03-14 Bristol-Myers Squibb Company Immunotherapeutic dosing regimens and combinations thereof
BR112012027995A2 (pt) * 2010-06-18 2017-01-10 Genentech Inc anticorpo e ácido nucleíco isolado, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, uso do anticorpo, método de tratamento de um indivíduo com câncer, de um indivíduo possuíndo um distúrbio imune, de inibição da angiogênese e para inibir a ativação constitutiva de axl
NZ714128A (en) 2010-09-09 2017-10-27 Pfizer 4-1bb binding molecules
KR20140104944A (ko) 2011-06-22 2014-08-29 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 항-ａｘｌ 항체 및 그의 용도
EP2723377B1 (en) 2011-06-22 2018-06-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-axl antibodies and uses thereof
WO2013180949A1 (en) * 2012-05-27 2013-12-05 Ning Xi Substituted quinoline compounds and methods of use
NZ711946A (en) 2013-03-14 2020-05-29 Icahn School Med Mount Sinai Newcastle disease viruses and uses thereof
TWI649308B (zh) * 2013-07-24 2019-02-01 小野藥品工業股份有限公司 喹啉衍生物
GB201410826D0 (en) * 2014-06-18 2014-07-30 Bergenbio As Anti-axl antibodies
GB201410825D0 (en) * 2014-06-18 2014-07-30 Bergenbio As Anti-axl antibodies
EP3226856A4 (en) 2014-12-02 2018-07-11 Celgene Corporation Combination therapies
US10208121B2 (en) * 2014-12-18 2019-02-19 Bergen Teknologioverforing As Anti-Axl antagonistic antibodies
GB201509338D0 (en) 2015-05-29 2015-07-15 Bergenbio As Combination therapy

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020105211A (ja) * 2015-05-29 2020-07-09 ベルゲンビオ エイエスエイＢｅｒＧｅｎＢｉｏ ＡＳＡ Ａｘｌインヒビタおよび免疫チェックポイントモジュレータまたは腫瘍溶解性ウィルスによる併用療法
JP2022141811A (ja) * 2015-05-29 2022-09-29 ベルゲンビオ エイエスエイ Ａｘｌインヒビタおよび免疫チェックポイントモジュレータまたは腫瘍溶解性ウィルスによる併用療法
JP7229194B2 (ja) 2015-05-29 2023-02-27 ベルゲンビオ エイエスエイ Ａｘｌインヒビタおよび免疫チェックポイントモジュレータまたは腫瘍溶解性ウィルスによる併用療法
JP7549627B2 (ja) 2015-05-29 2024-09-11 ベルゲンビオ エイエスエイ Ａｘｌインヒビタおよび免疫チェックポイントモジュレータまたは腫瘍溶解性ウィルスによる併用療法

Also Published As

Publication number Publication date
US20200215064A1 (en) 2020-07-09
GB201509338D0 (en) 2015-07-15
GB201516442D0 (en) 2015-10-28
JP2020105211A (ja) 2020-07-09
JP7549627B2 (ja) 2024-09-11
WO2016193680A1 (en) 2016-12-08
US20240277707A1 (en) 2024-08-22
EP3804723A1 (en) 2021-04-14
US20230149397A1 (en) 2023-05-18
EP3302481A1 (en) 2018-04-11
JP7229194B2 (ja) 2023-02-27
US20180153888A1 (en) 2018-06-07
JP2018521116A (ja) 2018-08-02
US11534440B2 (en) 2022-12-27
JP2022141811A (ja) 2022-09-29

Similar Documents

Publication Publication Date Title
JP7549627B2 (ja) Ａｘｌインヒビタおよび免疫チェックポイントモジュレータまたは腫瘍溶解性ウィルスによる併用療法
CN102281875B (zh) 预防、治疗或应对转移癌的使用axl抑制剂的组合疗法
JP5832524B2 (ja) ピリドン及びアザピリドン化合物、並びにそれらの使用方法
BR102018007822A2 (pt) composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição
EP2493313A1 (en) Kinase inhibitors
KR20150096769A (ko) 키나제 조절을 위한 화합물 및 방법, 및 그에 대한 적응증
CN111039946A (zh) 一类咪唑并芳环类化合物的制备和应用
JP2018528951A (ja) ＴＧＦβ受容体アンタゴニスト
KR20180042370A (ko) Tgf 베타 수용체 길항제
JP6856648B2 (ja) Ｃｘｃｒ４受容体アンタゴニスト
HK40049850A (en) Combination therapy
KR20180034548A (ko) Tgf 베타 수용체 길항제
AU2010313240B2 (en) Kinase inhibitors
HK40021327B (zh) 作为hpk1抑制剂的异喹啉
HK1164146B (en) Axl inhibitors for use in combination therapy for preventing, treating or managing metastatic cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180216

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180216

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181218

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190306

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190618

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20191105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200305

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20200305

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20200306

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20200415

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200515

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20200702

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20200707

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200825

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200930

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20201020

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20201112

R150 Certificate of patent or registration of utility model

Ref document number: 6795585

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250